What is CBIO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.55B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CBIO?

P/E (TTM) is n/a and 52-week range is $8.72 to $27.41 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CBIO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CBIO?

The company profile lists revenue (TTM) near $14M, net income (TTM) near $-13.75B, EPS (TTM) near $-7.41 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Crescent Biopharma Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Waltham, Massachusetts, US, 35.7M shares outstanding, ISIN KYG2545C1042 when available from company profile and filing metadata.

Crescent Biopharma Inc

$CBIO

Health Care · Biotechnology

IR Run Scenarios

$14.91

+5.59%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company is headquartered in Waltham, Massachusetts and currently employs 44 full-time employees. The company went IPO on 2014-01-10. The firm is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.

Employees

Website

www.crescentbiopharma.com/

IPO

2014-01-10

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)